echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Transplantation: Special immune cells can predict rejection response to organ transplants

    Transplantation: Special immune cells can predict rejection response to organ transplants

    • Last Update: 2020-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    , July 9, 2020 /--- PRNewswire/ -- In a recent study, researchers at Ohio State University School of Medicine have discovered immune cells that can predict the risk of possible organ rejection after a transplantThe findings could help develop treatments to prevent complications after transplant surgery(photo:
    the study, published in the journal Transplantation, followed 95 first-time kidney transplant patients within years of the transplantMonitor the development of DSA in patients for 1, 3, 6, 9 and 12 months after transplantationAll patients were DSA negative prior to transplant ationand and received standard immunosuppressive therapy after surgeryresults show that nearly 25 percent of patients have DSA (Donor-specific-antibodies)There were no significant differences in donor type (survival or death) or pre-transplant dialysis timeHowever, the number of CD8-T-specific subgroups of DSA-positive patients decreased significantly compared to patients who were DSA negative in the first year of transplantation"
    "A year of non-rejection and overall transplant survival in DSA-positive patients is lower than in DSA-positive patients, and the development of DSA is also associated with higher hospitalization rates, higher infection rates, and higher acute rejection responses," Bumgardner saidfuture studies will focus on strategies for monitoring receptor CD8 plus T cells to predict the risk of developing into DSA so that doctors can determine which patients can benefit from higher levels of immunosuppression targets, thereby preventing the development of DSA, or monitoring DSA more frequently to diagnose the risk of acute organ rejection at an earlier stageThe team is also exploring the possibility of creating treatment regimens using CD8 plus T cells before and after surgery(Bio Valley Bioon.com)source:Researchers identify immune cell that is the patient's risk of theof the original source:Zimmerer, J.M., et al(2020)Inverse Association Quantit O'O
    thdoi.org/10.1097/TP.0000000000003151.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.